Mark Yarchoan, MD, Johns Hopkins Medicine, Baltimore, MD, discusses results of multicenter dose escalation and expansion Phase I study (NCT03829436) investigating the small molecular selective antagonist of PPARα, TPST-1120, as a monotherapy and in combination with the anti-PD1 antibody, nivolumab, in patients with advanced solid tumors. Primary endpoints include incidence of dose limiting toxicities (DLTs), incidence of treatment adverse events, and identifying maximum tolerated dose of TPST-1120 as a monotherapy and in combination with nivolumab. Secondary outcomes include assessment of the maximum serum concentration and area under the curve (AUC), as well as objective response rate (ORR). A 30% ORR and 53% disease control rate (DCR) was observed in immunotherapy (IO)-refractory patients and IO-resistant indications with the combination treatment. TPST-1120 was well tolerated as a monothepray and in combination with nivolumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
